This study reveals crosstalk between autophagy and the Warburg effect in Saos-2 cells, where glycolytic stress triggers protective autophagy and its inhibition alters metabolism, promoting apoptosis.
Glucose uptake at sub-cytotoxic levels was quantified using the fluorescent analog 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose... These results demonstrate that phloretin selectively inhibits glucose uptake in liver cancer cells, likely through its high-affinity interaction with GLUT-2. Collectively, these findings highlight phloretin's potential as a metabolic therapeutic agent and support GLUT-2 as a viable target for HCC intervention.
The oncogenic phenotypes driven by TRIM47 overexpression on cellular viability and the cell cycle were counteracted by either administration of the glycolytic inhibitor 2-deoxy-D-glucose (2-DG) or by forced expression of FBP1...As the core effector molecule in the lactic acid-H3K18la epigenetic circuit, TRIM47 drives tumorigenesis by inducing ubiquitin-mediated degradation of FBP1. Targeting of this signaling axis holds significant promise for the development of new thyroid cancer therapies.
Cell models were established in BEAS-2B and NSCLC cell lines, with lactylation regulated by lactate (LA) and 2-deoxyglucose (2-DG)...Mechanistically, β-catenin K193 lactylation reduced LPO and increased GSH to suppress ferroptosis: lactylated β-catenin translocated to the nucleus, formed a complex with TCF4, and upregulated GPX4 transcription by binding its promoter. GPX4 overexpression reversed ferroptosis induced by β-catenin K193 lactylation inhibition, while blocking β-catenin/TCF4 interaction downregulated GPX4 and enhanced ferroptosis.
The dual-targeting LNP@2DG-DON nanoparticle synergistically combines metabolic and immune modulation, demonstrating superior antitumor effects compared to single-agent therapies. This approach represents a promising strategy for pancreatic cancer treatment, warranting further clinical investigation.
PFKP is a critical link between glycolysis and immune suppression in HCC. It promotes immune checkpoint expression and mTOR activation, suggesting a role in immune evasion. PFKP represents a dual biomarker for prognosis and immunotherapy response, and a promising target for combined metabolic and immune-based therapies.
1 month ago
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PFKP (Phosphofructokinase, Platelet)
2-Deoxy-D-glucose (2DG), a glycolytic inhibitor, depleted ATP dose-dependently (30-300 μM) and prevented those increases both at the protein and transcriptional levels. This was also observed in 3D spheroids upon TGF-β transient siRNA-mediated silencing or when TGF-βR1 kinase activity was inhibited by galunisertib...3D spheroids require ATP and a TGF-β/TGF-βR1 autocrine signaling axis to recapitulate the apoptosis/autophagy phenotypes. Combining glycolysis inhibition with TGF-β signaling inhibition could offer a promising therapeutic strategy for this rare and lethal brain cancer.
2 months ago
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • FASLG (Fas ligand) • TGFB1 (Transforming Growth Factor Beta 1) • CASP7 (Caspase 7) • PIK3C3 (Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3) • ATG16L1 (Autophagy Related 16 Like 1) • ATG7 (Autophagy Related 7)
Functionally, TBK1 promoted cell proliferation and colony formation while inhibiting apoptosis, which were attenuated by the glycolytic inhibitor 2-deoxy-D-glucose. These findings establish TBK1 as a critical mediator linking GM dysbiosis to metabolic reprogramming in CRC, suggesting that targeting the TBK1-glycolysis axis may represent a promising therapeutic strategy for delaying CRC progression.